Pharma/Biotech Update: Advancements in Inhibitor Therapy for Hemophilia A
December 9, 2013; Posted by: webleed staff
Biotech company, Selecta Biosciences, patenting filings on antigen-specific tolerogenic immunotherapies.
For those who suffer from autoimmune diseases, allergies and the chronic blood disorder, hemophilia A, there is continual advancement for inhibitor development.
According to a release by the Fort Mill Times, Selecta Biosciences has successfully demonstrated the efficacy of its antigen-specific immune tolerance products in animal models for several drug candidates, including SEL-201, a candidate for the treatment of undesirable neutralizing immune responses to Factor VIII replacement therapies in Hemophilia A.
“Hemophilia is one example of an orphan disease where Selecta’s tolerogenic immune therapies could make a decisive difference in patients’ life expectancy and quality of life,” said Ulrich von Andrian, MD, PhD, co-founder of Selecta and Mallinckrodt Professor of Immunopathology at Harvard Medical School.
For patients with hemophilia A (factor VIII deficiency), inhibitors look to have a valid opponent as these therapies become available.
Stay tuned for more information on these development patent findings. Click the link to read more about Selecta Biosciences, Inc.
Photo Credit – Selecta Biosciences, Inc.
